Foreign investors are stepping up acquisitions of Japanese drug makers. Under the Foreign Exchange and Foreign Trade Act (FEFTA), such…
BUSINESS
JCR, Takeda End Global Collab for Hunter Syndrome Therapy
JCR Pharmaceuticals said on June 25 that it has regained all licenses and commercialization rights to its Hunter syndrome drug JR-141 (pabinafusp alfa) from Takeda Pharmaceutical as they have agreed to end their collaboration for the product. The termination of…
To read the full story
Related Article
- JCR, Takeda Wind Up Collab on Gene Therapy Research
December 21, 2023
- JCR, Takeda Seal R&D Pact on Gene Therapies Using BBB Technology
March 29, 2022
- JCR’s Hunter Syndrome Drug Earns PRIME Tag in Europe
October 19, 2021
- Licensing Izcargo to Takeda First Step to Expanded Application of JCR’s BBB-Penetrating Technology: Chairman
October 8, 2021
- JCR Hooks Up with Takeda on Global Expansion of Hunter Syndrome Drug
October 1, 2021
BUSINESS
- Nihon Chouzai Tender Offer Completed, Set to Delist under Advantage Partners
September 18, 2025
- RaQualia’s Reflux Therapy Tegoprazan Debuts in India
September 18, 2025
- Eisai’s Etalanetug Snags FDA Fast Track Designation
September 18, 2025
- Daito Wins China Approval for Celecoxib, 2nd Generic in Market
September 18, 2025
- Alnylam Sees Japan Business Doubling as Amvuttra Expands into ATTR-CM
September 17, 2025
MSD’s new pulmonary arterial hypertension (PAH) therapy Airwin (sotatercept) hit the Japanese market in mid-August. It’s the kind of launch…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…